Home / Peptides / Selank: Is It Approved? What the Evidence Actually Shows
Selank: Is It Approved? What the Evidence Actually Shows
Selank is not FDA-approved or in HHS's peptide policy. The human and animal studies that exist, FDA's safety concerns, and how it differs from semax.
On this page
Quick facts
Fact sheet
- U.S. status
- Strongest evidence
- Limited human data
- Status verified
Selank is often mentioned next to semax, but the two stand in different places. FDA reviewed semax’s effectiveness, and HHS’s new policy names it. Neither is true of selank, and the human evidence we found is a brain-imaging study in healthy volunteers.
Key takeaways
- Selank is not FDA-approved. As of Nov. 4, 2026, Drugs@FDA lists no product containing it, and we found no FDA-approved label.
- Selank is not among the six peptides in HHS’s Oct. 30, 2026 interim policy. Semax is. Treating them alike is a mistake.
- What we found: a small brain-imaging study in healthy volunteers and studies in rats. We did not find a clinical trial showing it treats anxiety.
- FDA says it lacks important information about selank’s safety in humans. FDA also names a possible risk of immune reactions.
- Our search was limited. We read mostly abstracts and did not read Russian-language studies, so more research may exist.
Is selank FDA-approved?
No. As of Nov. 4, 2026, Drugs@FDA lists no product containing selank, and we found no FDA-approved label. Drugs@FDA covers approved products, not pending applications.
Some websites say selank is a registered drug in Russia. We could not verify that, and we did not read Russian regulatory records. A registration in another country would not be U.S. approval.
Is selank covered by HHS’s new peptide policy?
No. On Oct. 30, 2026, HHS published an interim policy naming six peptides: BPC-157, TB-500, epitalon, semax, KPV and MOTS-c, each under conditions and for specific forms. Selank is not on that list (HHS policy, Appendix A). The policy is enforcement discretion for those six, not an approval, and it does not extend to selank.
What is selank’s standing with FDA’s compounding lists?
- Category 2 history. FDA’s page on substances that may present significant safety risks lists selank acetate among substances whose nominations were withdrawn. It is no longer in Category 2.
- Not on the lists we checked. We did not find selank on FDA’s 503A Category 1 list or on FDA’s list of substances nominated under 503B.
- No FDA advisory review that we found. A law-firm account (secondary source) of the advisory committee’s planned meeting before the end of February 2027 does not list selank among the peptides expected.
We make no claim here about whether selank can legally be compounded. Compounded versions are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. For the wider picture, see are peptides legal in the US.
What studies of selank exist?
We found no randomized trial of selank with a clinical result that we could read. We read these through their abstracts.
| Type | What was found | What it does not show |
|---|---|---|
| Human imaging | A study of resting brain connectivity in 52 healthy volunteers compared selank with semax and placebo | A scan result is a marker. It does not measure anxiety, memory or focus, and the volunteers were healthy |
| Animals | Studies in rats reported fewer signs of morphine withdrawal, less stress-related liver damage and changes in GABA-related genes (2022, 2019, 2016) | Results in rats do not carry over reliably to people |
| Registered trials | A ClinicalTrials.gov search returns two records, but they are brain-stimulation studies that match only through a shared code name. We found no trial of selank itself | A registry search cannot show work that was never registered there |
An article from 2016 says “clinical studies have shown” effects similar to benzodiazepines, but its abstract gives no data for that, and we do not treat it as evidence.
For how we weigh these types of evidence, see how we rate peptides.
How does selank differ from semax?
| Selank | Semax | |
|---|---|---|
| FDA effectiveness review we found | None | FDA reviewed it for three uses and found “insufficient evidence of effectiveness” for each (FDA) |
| In HHS’s Oct. 30, 2026 policy | No | Yes, one form only (free base, intranasal), under conditions |
| Human evidence we found | One imaging study in healthy volunteers | Open-label and healthy-volunteer studies, described through FDA’s review |
| Controlled trial of cognition we found | None | None |
See our guide to semax for its details, and peptides for cognitive function for both together.
What are the risks?
- Little safety information in humans. FDA says it “lacks important information regarding any safety issues raised by selank acetate administered to humans” (FDA).
- Immune reactions. FDA names a possible risk of immune reactions, from aggregation and impurities.
- Long-term safety, interactions and dependence. We found no data.
Which claims are not supported?
- “A proven anti-anxiety peptide.” We found no clinical trial showing it treats anxiety.
- “Safer than benzodiazepines.” We saw no trial that supports it.
- “Included in the new HHS decision along with semax.” It is not.
- “Approved in Russia, so it’s proven.” We could not verify the registration, and a registration elsewhere is not evidence reviewed by FDA.
- “Improves memory and focus.” We did not find evidence for that.
- “No side effects.” Not shown.
What should you ask your doctor?
- What is behind my anxiety, stress or trouble concentrating, and what evidence-based options exist?
- If selank is suggested, what human evidence supports it for my goal, and who prepares it?
- Is the product FDA-approved or compounded, and would it be covered by any FDA policy?
- Could it interact with medicines I take?
We do not give doses, cycles or preparation instructions, and we do not recommend sellers.
Frequently asked questions
Is selank FDA-approved?
No. As of Nov. 4, 2026, Drugs@FDA lists no product containing it. Some websites say it is registered in Russia; we could not verify that, and it would not be U.S. approval.
Is selank covered by the HHS policy?
No. The Oct. 30, 2026 policy names six peptides, and selank is not one of them.
Does selank work for anxiety?
We found no clinical trial showing that it does. We found a small brain-imaging study in healthy volunteers and studies in rats.
Is selank the same as semax?
No. They are different peptides with different regulatory standing. FDA reviewed semax’s effectiveness and HHS’s policy names it; neither is true of selank.
Is selank safe?
We cannot say. FDA says it lacks important information about selank’s safety in humans, and we found no data on long-term safety.
From Best Peptides Today
Sources we checked
- FDA: bulk drug substances that may present significant safety risks (Category 2)FDA. Accessed .
- FDA 503A Category 1 list (updated May 14, 2026)FDA. Accessed .
- FDA: bulk drug substances nominated under section 503B, by category (updated March 21, 2025)FDA. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- McDermott+: PCAC votes on peptides (secondary source)Other. Accessed .
- FDA presentations to the Pharmacy Compounding Advisory Committee on semax (July 24, 2026)FDA. Accessed .
- Selank and semax effects on resting brain connectivity in healthy volunteers (PubMed)PubMed. Accessed .
- Selank in rats, 2022 (PubMed)PubMed. Accessed .
- Selank in rats, 2019 (PubMed)PubMed. Accessed .
- Selank in rats, 2016 (PubMed)PubMed. Accessed .
- ClinicalTrials.gov search for selankClinicalTrials.gov. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.